FDA Alerts

The FDA has approved Jynneos, a new live, non-replicating vaccination for the prevention of smallpox and monkeypox in adults aged 18 years and older who are at high risk for the diseases.

The FDA has approved the first glucagon-like peptide receptor protein treatment in the US that is not given via injection.

An FDA advisory committee has recommended the approval of the first therapy for peanut allergies.

The NHE3 sodium transport inhibitor was approved for use after results from 2 clinical trials showed increased bowel movements and decreased abdominal pain among individuals with IBS-C.

The FDA have identified several ingredients that may be connected to the recent reports of individuals with severe respiratory illness in connection with use of electronic smoking products.

Previously to this drug’s approval, there were no treatment options for adults with interstitial lung disease associated with systemic sclerosis or scleroderma.

Previously to this drug’s approval, there were no treatment options for adults with interstitial lung disease associated with systemic sclerosis or scleroderma.

The FDA issued a drug safety warning after more than 60 individuals experienced liver injury after they received treatment with 1 of 3 medications for hepatitis C virus.

After 4 clinical trials showed the treatment decreased daily “off” time, the FDA approved this new add-on therapy for adults with Parkinson disease.

The FDA has approved a new antibiotic available in both an oral and injectable form, for the treatment of community-acquired bacterial pneumonia in adults.